Posts

Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War

on

Gilead Cancels Midstage HIV Trial as FDA Clinical Hold Remains Intact

on

Gilead Acquires Ouro Medicines for Up to $2.18 Billion to Advance T Cell Engager Autoimmune Therapies

on

Gilead Sciences Acquires Arcellx in $7.8 Billion Deal to Control CAR-T Cell Therapy

on

Gilead Tops 4Q Expectations but Yeztugo Forecast Disappoints with Weak 2026 Guidance

on

‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure

on

Vera Therapeutics Appoints James R. Meyers to Its Board of Directors

on

Gilead Cell Therapy Sales Drop 11% in Q3 2025, HIV Franchise Drives Growth

on

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

on

Assembly Bio Reports Phase 1b Success in Herpes; Gilead Increases Stake with 2.3M Shares

on

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

on

Kymera Snags Gilead as New Partner; Sanofi Opts for Next-Gen IRAK4 Degrader

on

FDA Approves Gilead's Twice-Yearly HIV Prevention Shot

on

Gilead Lays Off 36 Employees After Cancelling Oceanside, California Expansion

on

FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns

on

Gilead Bolsters Trodelvy in Triple-Negative Breast Cancer With Practice-Changing Keytruda Combo Win

on

Gilead's Seladelpar Receives Conditional EU Approval for Primary Biliary Cholangitis Treatment

on

Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir

on